TSTL Share Price Performance
UK£3.92
0.32 (8.89%)
12.5% undervalued intrinsic discount
UK£4.48
Fair Value
Price UK£3.92
AnalystConsensusTarget UK£4.48
Brenin UK£2,253.64
Fair ValueUK£4.48
Share Pricen/a
Tristel plc Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 31 Fair Values set on narratives written by author
TSTL Community Narratives
AN
Fair Value
·Fair Value UK£4.48 12.6% undervalued intrinsic discount
US Expansion And Direct Sales Will Open New Opportunities
1users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
BR
Fair Value
·Fair Value UK£2.25k 99.8% undervalued intrinsic discount
Tristel's US Expansion Could Spark a 286% Revenue Surge
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Tristel's US Expansion Could Spark a 286% Revenue Surge
A case for buying shares in AIM: TSTL Tristel currently rests on a combination of recent share-price weakness and improving business fundamentals. The share price has fallen to around GBX 385–390p in mid-March 2026 after trading above GBX 420–430p earlier in the year, leaving it noticeably below its recent range and close to the middle of its 52-week band of roughly GBX 260p–445p.Read more
US Expansion And Direct Sales Will Open New Opportunities
Key Takeaways Geographic expansion, especially into the U.S., is expected to drive significant revenue growth in medical device decontamination. A shift to direct sales and strong OEM partnerships could enhance profitability by capturing more value and increasing product adoption rates.Read more
AN
UK£4.48
12.6% undervalued intrinsic discount
Fair Value
Revenue
11.06% p.a.
Profit Margin
17.67%
Future PE
24.94x
Price in 2028
UK£5.51
Trending Discussion
Recently Updated Narratives
BR
Tristel's US Expansion Could Spark a 286% Revenue Surge
Fair Value: UK£2.25k 99.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
US Expansion And Direct Sales Will Open New Opportunities
Fair Value: UK£4.48 12.6% undervalued intrinsic discount
17 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Flawless balance sheet with solid track record and pays a dividend.
1 Risk
4 Rewards
Tristel plc Key Details
About TSTL
- Founded
- 1993
- Employees
- 270
- CEO
- WebsiteView website
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wipes, sporicidal wipes, clean for Stella, protect, and wipes; surface disinfection products, such as FUSE, JET, JET LUX, JET PRO, TANK 10 CLO2, TANK 5 CLO2, and TILT 5 CLO2; as well as operates 3T, a cloud-based platform alternative to paper-based traceability systems. The company provides its medical disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
